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A Randomised Controlled Trial of Micronised Purified Flavonoid Fraction
vs Placebo in Patients with Chronic Venous Disease
G. Danielsson∗, C. Jungbeck, K. Peterson and L. Norgren
Section of Vascular Surgery, Department of Surgery, Lund University Hospital, Sweden
Objective: to evaluate the efficacy of a micronised purified flavonoid fraction (MPFF) in the treatment of chronic venous
disease (CVD).
Design: prospective double blind, randomised, control study.
Patients and methods: one hundred and one patients with symptomatic CVD were randomly allocated to treatment
for 60 days with either MPFF (51 patients) or placebo (50 patients) 500 mg twice daily. There were 28 men and 73
women, aged 22–65 years (mean age 48 years). No difference regarding age, gender, clinical class or duration of symptoms
was recorded between the treatment and placebo groups. A global score for evaluation of symptoms was used. Patients
were investigated with plethysmography (foot-volumetry) and duplex-ultrasonography before and after the treatment
period. For statistical comparison Cochran-Mantel-Haenszel test, two-sided Student t-test and covariance analysis were
used and p<0.05 was regarded significant.
Results: improvement of the global score of symptoms was reported by 21 patients in the MPFF group and by 16 in the
placebo group (N.S.). For the whole groups, no significant differences were recorded before and after treatment regarding
foot-volumetric or ultrasonographic parameters. On the other hand, in patients with edema (20 in the MPFF group, 23
in the placebo group) ultrasonographic reflux time was significantly reduced for those in the treatment group (p=0.03).
This finding did not correlate to clinical symptoms.
Conclusion: in this study, MPFF did not change the symptoms of CVD, except night cramps. A secondary finding was
reduced reflux times in patients with oedema, although no ultrasonographic or foot-volumetric parameters changed
significantly for the whole group. The role of MPFF in treatment of patients with CVD needs to be further analysed in
a large population.
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Introduction with chronic venous insufficiency.5 MPFF has also been
shown to decrease the level of soluble plasma markers
Pharmacological treatment for chronic venous disease of endothelial activation in patients with CVD.6 Even
a beneficial effect on ulcer healing has been noted.7(CVD) is frequently used in many countries, though
in Scandinavia drugs are hardly ever prescribed for Other effects that have been attributed to MPFF are
inhibition of the prostaglandin synthesis, protectionCVD. Studies have shown beneficial effects of a mi-
cronised purified flavonoid fraction (MPFF) in patients against free radicals, activation of the complement
system and increased lymphatic drainage.8 Based onwith a malfunction in the “venolymphatic cir-
culation”.1–3 In these studies most of the patients had the beneficial effects of MPFF on the microcirculation
it was found valuable to perform a placebo controlled“functional venous insufficiency” and 48%, 58% and
100% of included patients respectively had no objective trial of MPFF in an unselected group of patients suf-
fering CVD in Sweden. The objectives were to findsigns of CVD. Utilising strain gauge plethysmography,
some beneficial effects of MPFF have been observed out a possible correlation between clinical outcome
and change of foot volumetric and duplex parameters,on venous parameters, decreased venous capacity,
decreased venous distensibility and lowered venous under the hypothesis that MPFF reduces symptom of
CVD and improves venous function.outflow time compared to placebo.3 An increased ven-
ous tone has also been observed in normal legs.4 It
has been concluded that MPFF is of benefit to patients
Patients and Methods
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As both subjective clinical and objective parameters
were included it was not possible to determine a
priori any expected difference between the outcome
for patients on placebo and those on active treatment,
respectively. One hundred and one patients with
symptomatic CVD were randomly allocated to treat-
ment for 60 days with either MPFF (51 patients) or
placebo (50 patients) twice daily. There were 28 men
and 73 women, aged 22–65 years (mean age 48 years).
No difference regarding age, gender or duration of
symptoms was recorded between the treatment and
placebo groups. Sixty-nine percent of the patients had
a family history of venous disorders (Table 1). The
clinical class was comparable between the groups with
most patients belonging to C2 (Fig. 2).
Foot-volumetry10 was performed in the standing
position and patients were asked to perform 20 knee-Fig. 1. Description of the study population.
bends during a 40-s period. Expelled venous volume
as well as refilling rate after exercise was calculated.
duplex-ultrasonography and plethysmograpy (foot- The duplex investigation was performed supine, sit-
volumetry) during the inclusion period that lasted for ting and 60° vertical to detect venous obstruction and
20 months from 13 January 1997 to 18 October 1998. reflux at the femoral, popliteal and posterior tibial
The completion date of the study with follow up on vein as well as in the long and short saphenous veins
all patients was 18 December 1998. Over 800 patients respectively (six levels). Pneumatic cuff with automatic
were investigated during this period and those that inflation/release was used to evaluate the reflux time.
had substantial symptoms, with duplex-ultrasound A reflux time >0.5 s was considered pathological. After
verified reflux, and fulfilling inclusion criteria, were a treatment period of 60 days, clinical examination,
invited to participate in the study (Fig. 1). The inclusion duplex-ultrasound and foot-volumetry were repeated
criteria were an age between 18–65 years and symp- and the patients were asked about their symptoms
toms from the lower leg attributable to venous in- as above, their overall opinion of the treatment and
sufficiency. Exclusion criteria were diabetes, possible side effects. A single vascular surgeon was
inflammatory disease, heart disease, renal disease, seeing all patients at both visits.
liver disease or peripheral arterial disease. Patients The Lund University Ethical Committee approved
with potential allergic reactions to venoactive drugs, the study. Results were compared between groups
patients’ currently taking anti-inflammatory drugs using Cochran-Mantel-Haenszel test for categorical
(steroids, NSAID) or diuretics were also excluded. In variables and two-sided Student’s t-test or one-way
cases with symptoms from both legs only the leg with analysis of covariance for continuous variables. A
the most severe symptoms was included. p-value <0.05 was regarded significant.
After informed consent, patients were randomised
in a blinded fashion (sealed envelope principle) to
treatment with MPFF (Daflon 500 mg, containing 90%
diosmin and 10% flavonoids expressed as hesperidin; Results
IRIS, 92415, Courbevoie Cedex, France) or placebo
b.i.d. Information was gathered about the family his- Four patients withdrew, one in each group because of
nausea, one in the placebo group who got pregnanttory of venous disease, time since occurrence of symp-
toms, former surgical or medical treatment, smoking and one in the MPFF group for reasons unrelated to
the therapy. Of 97 patients that fulfilled the treatmentand drinking habits. The following symptoms were
analysed, heaviness, tiredness, ankle swelling, pain 48 were in the MPFF group and 49 in the placebo
group. Mild side effects were reported by 12% of theand night cramps and the patients were asked to give
each symptom a score between 0 and 3, where 0= MPFF group compared to 4% in the placebo group.
Patients overall opinion of the treatment was excellentnone, 1=mild, 2=moderate, 3=severe. Side effects
were recorded in a similar way using a score from 0 or good in 40% of the MPFF group compared to 26%
in the placebo group, none or worse in 37% of theto 3. Each patient was examined and classified ac-
cording to the CEAP classification.9 MPFF group and 44% of the placebo group.
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Table 1. Patients’ characteristics.
MPFF (n=51) Placebo (n=50)
Mean age (range) (years) 48 (22–65) 48 (31–63)
Male/Female 12/39 16/34
Family history of CVD 72% 66%
Duration of symptoms 10 years 10 years
Mean, (range) (5 months–45 years) (3 months–38 years)
Table 3. Ultrasonographic reflux time (s) in patients with oedema
at inclusion. Value as mean (S.D.) (sum on six levels).
MPFF Placebo
(n=20) (n=23)
Inclusion visit 4.34 (2.74) 5.26 (2.12)
After 60 days 3.66 (1.84) 5.46 (2.62)∗
∗ p=0.03.
(Table 3). This finding did not correlate to clinical
symptoms.
Fig. 2. Clinical class at inclusion (CEAP classification).
Discussion
Table 2. Foot volumetric changes after 60 days treatment period.
Mean (S.D.). A number of drugs with proposed venoactive prop-
erties are available. The Task Force on Chronic VenousMPFF Placebo
Disorders of the lower leg pointed out that most of
Foot volume∗ +11.9 (43.4) +4.4 (29.2) (N.S) the trials on venoactive drugs were performed during
EV rel.† +0.017 (0.336) +0.118 (0.333) (N.S) the 1960s or 1970s and they rarely comply with currentQ‡ −0.250 (2.394) −0.003 (1.847) (N.S)
scientific standards for clinical trials.11 The positive
∗ Foot volume in ml. effects of venoactive drugs have mainly been a re-
† Expelled volume related to foot volume in ml/100 ml. duction of subjective symptoms and oedema and most‡ Refilling rate in ml/min×100 ml.
of the studies have included patients representing such
problems, and not those with an objectively proven
CVD. Rutosides have been shown to improve the
subjective symptom of swelling and relieve crampsImprovement of the global score of symptoms was
reported by 21 patients in the MPFF group and by but otherwise with no effect on symptoms when com-
pared to placebo.12 Other studies have not been able16 in the placebo group. (N.S.) Night cramps were
significantly reduced in patients after active treatment to confirm the effect of rutosides on the subjective
symptom of swelling.13,14 Calcium dobesilate15 and di-(p=0.03), with all other symptoms (heaviness, tired-
ness, pain and ankle swelling) remaining unchanged hydroergocristine16 have been shown to relieve night
cramps, pain and aching more effectively than placebo.in both groups. For the whole groups, no significant
differences were recorded before and after treatment MPFF has been shown to reduce the total score of
symptoms in patients with functional and organicregarding foot-volumetric or ultrasonographic para-
meters. Neither foot volume nor expelled volume re- venous insufficiency in 71% and 66% respectively,
compared to 36% and 38% respectively for the placebolated to foot volume changed significantly in any of
the groups (Table 2). group.2 Former studies on the effect of MPFF have
included patients with all kinds of symptoms fromA numerical reduction in reflux time was noted for
the entire MPFF group although this reduction was the lower leg, common for patients with CVD, but
also present without CVD. It is of importance to estab-not significant compared to placebo. (N.S.) In patients
with oedema (20 in the MPFF group, 23 in the placebo lish the presence of CVD, if a drug treatment should
be recommended based on the objective effect of thegroup) ultrasonographic reflux time was significantly
reduced for patients in the treatment group (p=0.03) drug, not only to rely on more or less badly defined
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circulation of the lower limb. A double-blind placebo controlledsymptoms. CVD should be defined as an abnormally
study. Phlebology 1994; 21: 67–70.functioning venous system caused by venous valvular 2 Laurent R, Gilly R, Frileux C. Clinical evaluation of a ven-
incompetence with or without associated venous out- otropic drug in man. Example of Daflon 500 mg. Int Angiol 1988;
7: 39–43.flow obstruction, which may affect the superficial ven-
3 Tsouderos Y. Are the phlebotonic properties shown in clinicalous system, the deep venous system, or both and pharmacology predictive of a therapeutic benefit in chronic
proven with objective measures.9 venous insufficiency? Our experience with Daflon 500 mg. Int
Angiol 1989; 8: 53–59.This is to the best of our knowledge the first con-
4 Amiel M, Barbe R. Study of the pharmacodynamic activity oftrolled study on the effect of a venoactive drug, with
daflon 500 mg. Ann Cardiol Angeiol (Paris) 1998; 47: 185–188.
an objectively verified venous insufficiency utilising 5 Geroulakis G, Nicolaides AN. Controlled studies of Daflon
500 mg in chronic venous insufficiency. Angiology 1994; 45: 549–duplex-ultrasound and plethysmography. Patients in-
553.cluded in the present study had to a great extent low
6 Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial
grade CVD (43% varicose veins only), which might activation response to oral micronised flavonoid therapy in
explain the overall results with only a tendency to patients with chronic venous disease – a prospective study. Eur
J Vasc Endovasc Surg 1999; 17: 313–318.symptomatic improvement. The effects of MPFF, re-
7 Guilhou JJ, Dereure O, Marzin L et al. Efficacy of Daflonduction of capillary leakage,17 less activation of white 500 mg in venous leg ulcer healing: a double-blind, randomized,
cells18 and increase of venous tone4 suggest that controlled versus placebo trial in 107 patients. Angiology 1997;
48: 77–85.patients with oedema and more severe CVD may
8 Struckmann JR, Nicolaides AN. Flavonoids. A review of thebenefit most from the treatment. The result achieved pharmacology and therapeutic efficacy of Daflon 500 mg in
in patients with oedema is in line with this theory. patients with chronic venous insufficiency and related disorders.
Angiology 1994; 45: 419–428.Although only duplex-ultrasound measurements of a
9 Porter JM, Moneta GL. Reporting standards in venous disease:reduced reflux were of a significant magnitude there
an update. International Consensus Committee on Chronic Ven-
was a tendency to similar findings in the foot- ous Disease. J Vasc Surg 1995; 21: 635–645.
10 Norgren L. Functional evaluation of chronic venous in-volumetric parameters. These results suggest that
sufficiency by foot volumetry. Acta Chir Scand 1974; 444: 1–48.medical treatment can reduce reflux, which might be
11 Kurz X, Kahn SR, Abenhaim L et al. Chronic venous disordersan effect of venoconstriction. The clinical relevance of of the leg: epidemiology, outcomes, diagnosis and management.
a shorter reflux time in patients with oedema on active Summary of an evidence-based report of the VEINES task force.
Venous Insufficiency Epidemiologic and Economic Studies. Inttreatment is, however, uncertain.
Angiol 1999; 18: 83–102.Although no significant changes were seen re- 12 Prerovsky I, Roztocil K, Hlavova A et al. The effect of hydroxy-
garding symptoms in these patients, a higher dosage ethylrutosides after acute and chronic oral administration in
patients with venous diseases. A double-blind study. Angiologicaof MPFF could possibly be more effective. In a study
1972; 9: 408–414.on blood flow in the hamster cheek pouch, MPFF
13 de Jongste AB, Jonker JJ, Huisman MV, ten Cate JW, Azar
was able to improve the microvascular reactivity after AJ. A double blind three center clinical trial on the short-term
efficacy of 0-(beta-hydroxyethyl)-rutosides in patients with post-ischaemia/reperfusion in a dose dependent way.19 As
thrombotic syndrome. Thromb Haemost 1989; 62: 826–829.capillary leakage and white cell activation are events
14 Kranendock S, Koste A. A double blind clinical trial of the
that could be prevented by MPFF, further in- efficacy and tolearbeility of O-(b-hydroxyethyl)-rutosides and
vestigations are mandatory in patients with more ad- compression stockings in the treatment of leg oedema and
symptoms following surgery for varicose veins. Phlebology 1993;vanced venous disease (C3–C6).
8: 77–81.In conclusion, the present study does not give evi- 15 Widmer L, Biland L, Barras JP. Doxium 500 in chronic venous
dence for MPFF treatment for all stages of CVD. insufficiency: a double-blind placebo controlled multicentre
study. Int Angiol 1990; 9: 105–110.The findings in patients with oedema warrant further
16 Languillat N, Vecchiali J, Zuccarelli F, Bouxin A. Essai enstudies as they may benefit most of treatment with double aveugle contre placebo des effects du Vasobral dans les
venoactive drugs. troubled de la permeabilite capillaire lies a linsuffisance veineuse
par le test isotopique de Landis. Angilogie 1986; 39: 1–4.
17 Cesarone MR, Laurora G, De Sanctis MT, Belcaro G. Ca-
pillary filtration and ankle edema in patients with venous hyper-Acknowledgement
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